Estimated Plasma Volume and Heart Failure-Related Events in Hospitalized Patients With Stage A–D Heart Failure

Abstract

BACKGROUND: Heart failure (HF) is associated with poor clinical outcomes and is classified into Stages A-D. Estimated plasma volume (ePV) is a marker of plasma volume expansion. Prognostic markers applicable across all HF stages may enable the early identification of patients at high risk of adverse clinical outcomes. This study evaluated the impact of ePV on clinical outcomes in patients with Stage A-D HF. METHODS AND RESULTS: ePV was measured using the PRIME Plus analyzer in 494 patients with HF (Stage A, n=78; Stage B, n=274; Stage C/D, n=142) admitted to our hospital in 2022. Over a median follow-up of 3 years, 95 HF-related events, defined as HF rehospitalization and deaths, and 43 all-cause deaths occurred. Kaplan-Meier analysis demonstrated that patients in the highest ePV tertile had the greatest risk of HF-related events and all-cause deaths. Multivariable Cox proportional hazards regression analysis identified ePV as an independent predictor of HF-related events (hazard ratio [HR] 1.48; 95% confidence interval [CI] 1.26-1.73; P<0.0001) and all-cause deaths (HR 1.35; 95% CI 1.06-1.73; P=0.0158). The addition of ePV to established cardiovascular risk factors significantly improved the C-statistic (0.7009 vs. 0.7415; P=0.0260), net reclassification index, and integrated discrimination index. CONCLUSIONS: This study demonstrates that ePV is a feasible prognostic marker for HF-related events and all-cause deaths in patients with Stage A-D HF.

Heart Failure Is Associated with Limb-Related Adverse Events in Patients Hospitalized for Diabetic Foot Ulcers
Federico Rolando Bonanni, Alessandro Minasi, Aikaterini Andreadi +5
Journal of Clinical Medicine1 Oct 2026Peer-reviewedCC BY 4.0Full textEndocrinology & metabolismCrossrefEurope PMC
Predictive value of combined estimated plasma volume status and neutrophil-to-lymphocyte ratio for cardiovascular mortality in patients with acute myocardial infarction with heart failure
Caizhi Dai, Xiaomin Chen, Xiuting Chen +1
Frontiers in cardiovascular medicine16 Oct 2026Peer-reviewedCC BYFull textCardiovascular medicineEurope PMC
Response by Baudry et al to Letter Regarding Article “Interplay Between Acute Heart Failure and COPD in Patients Hospitalized for Dyspnea: Prognostic Insights From the PARADISE Cohort”
Guillaume Baudry, Tahar Chouihed, Nicolas Girerd
ESC Heart Failure7 Sep 2026Peer-reviewedCC BY-NC 4.0Full textCardiovascular medicineHAL
In-Hospital Guideline-Directed Medical Therapy Intensification and Long-Term Outcomes in Patients Hospitalized for Heart Failure in the Current Clinical Paradigm ― Insights From the QHEART-R Study ―
Toru Hashimoto, Ryuichi Matsukawa, Shouji Matsushima +15
Circulation Journal3 Oct 2026Peer-reviewedCC BY-NC-NDFull textCardiovascular medicineJ-STAGE
Intensive pharmacist-led guideline-directed medical therapy for hospitalized heart failure patients: a single-center retrospective cohort study.
Hikaru Katagiri, Komei Tanaka, Ryuji Kobayashi +8
Journal of pharmaceutical health care and sciences3 Aug 2026Peer-reviewedCC BYFull textCardiovascular medicineEurope PMCPMC

Cite

BibTeX RIS

BibTeX

@article{otaki2026estimated,
  title = {{Estimated Plasma Volume and Heart Failure-Related Events in Hospitalized Patients With Stage A–D Heart Failure}},
  author = {Yoichiro Otaki and Tetsu Watanabe and Rin Kitagawa and Sakyo Urasawa and Daisuke Kinoshita and Masahiro Wanezaki and Shigehiko Kato and Harutoshi Tamura and Takanori Arimoto and Masafumi Watanabe},
  journal = {Circulation Journal},
  year = {2026},
  month = oct,
  doi = {10.1253/circj.cj-25-1164},
  url = {https://www.jstage.jst.go.jp/article/circj/90/11/90_CJ-25-1164/_article},
  note = {CC BY-NC-ND},
}

RIS

TY  - JOUR
TI  - Estimated Plasma Volume and Heart Failure-Related Events in Hospitalized Patients With Stage A–D Heart Failure
AU  - Yoichiro Otaki
AU  - Tetsu Watanabe
AU  - Rin Kitagawa
AU  - Sakyo Urasawa
AU  - Daisuke Kinoshita
AU  - Masahiro Wanezaki
AU  - Shigehiko Kato
AU  - Harutoshi Tamura
AU  - Takanori Arimoto
AU  - Masafumi Watanabe
PY  - 2026
DA  - 2026/10/23
JO  - Circulation Journal
DO  - 10.1253/circj.cj-25-1164
UR  - https://www.jstage.jst.go.jp/article/circj/90/11/90_CJ-25-1164/_article
AB  - BACKGROUND: Heart failure (HF) is associated with poor clinical outcomes and is classified into Stages A-D. Estimated plasma volume (ePV) is a marker of plasma volume expansion. Prognostic markers applicable across all HF stages may enable the early identification of patients at high risk of adverse clinical outcomes. This study evaluated the impact of ePV on clinical outcomes in patients with Stage A-D HF. METHODS AND RESULTS: ePV was measured using the PRIME Plus analyzer in 494 patients with HF (Stage A, n=78; Stage B, n=274; Stage C/D, n=142) admitted to our hospital in 2022. Over a median follow-up of 3 years, 95 HF-related events, defined as HF rehospitalization and deaths, and 43 all-cause deaths occurred. Kaplan-Meier analysis demonstrated that patients in the highest ePV tertile had the greatest risk of HF-related events and all-cause deaths. Multivariable Cox proportional hazards regression analysis identified ePV as an independent predictor of HF-related events (hazard ratio [HR] 1.48; 95% confidence interval [CI] 1.26-1.73; P<0.0001) and all-cause deaths (HR 1.35; 95% CI 1.06-1.73; P=0.0158). The addition of ePV to established cardiovascular risk factors significantly improved the C-statistic (0.7009 vs. 0.7415; P=0.0260), net reclassification index, and integrated discrimination index. CONCLUSIONS: This study demonstrates that ePV is a feasible prognostic marker for HF-related events and all-cause deaths in patients with Stage A-D HF.
SN  - 1347-4820
SN  - 1346-9843
ER  -